ArticleCureus2024
Post-Stevens-Johnson Syndrome Bronchiolitis Obliterans: Report of a Complex Case and a Literature Review.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiolitis obliterans (BO) is a rare and severe respiratory complication of Stevens-Johnson syndrome (SJS), which primarily affects the small airways and causes progressive respiratory decline. We present the case of a young male with autism spectrum disorder who developed BO after an episode of SJS triggered by amoxicillin. Initially, the patient presented with an ulcerative rash and respiratory symptoms and received high-dose corticosteroids, leading to partial resolution of mucocutaneous lesions. However, his respiratory symptoms progressively worsened, and he was initially misdiagnosed with asthma, which delayed the appropriate treatment. Imaging and pulmonary function tests (PFTs) revealed findings consistent with BO, including mosaic attenuation, airway thickening, and severe obstruction without reversibility. After infectious and autoimmune causes were ruled out, management included high-dose corticosteroids and fluticasone, azithromycin, and montelukast (FAM) therapy, resulting in partial clinical improvement. Recognising the progressive nature of post-SJS BO, the patient was referred to a tertiary centre for lung transplantation. This case highlights the importance of early diagnosis and tailored management, including potential transplantation, in patients with severe post-SJS BO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.